Huntington Hospital, a specialist in stroke care, has collaborated with Viz.ai to launch its first US FDA approved computer-aided triage system in the Los Angeles area, it was reported on Wednesday.
Huntington Hospital has installed this applied artificial intelligence-based technology to help facilitate early access to the most advanced stroke care. Viz.ai solutions is intended to enable Huntington Hospital to further improve the power of its stroke care team through rapid detection and notification of suspected LVO strokes and allow stroke specialists to securely communicate to synchronise care and determine the optimal patient treatment decision.
Arbi Ohanian, MD, medical director of Huntington Hospital's Stroke Program, Huntington Hospital, said, 'With stroke, time is brain. Viz.ai's applied artificial intelligence solutions have been developed by top stroke clinicians and technical experts in the world and we are excited to be able to bring these transformational technologies to Huntington Hospital and our community. It truly changes the way that we deliver stroke care which we believe will result in improved outcomes for our patients.'
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial